How many institutional investors hold SRPT?

4 tracked institutional investors disclosed a position in SRPT (SAREPTA THERAPEUTICS INC) in their most recent 13F filing.

Who is the largest institutional holder of SRPT?

Ken Griffin, Citadel Advisors, holds the largest disclosed position in SRPT, valued at $50M.

Where does this SRPT ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

SRPT — SAREPTA THERAPEUTICS INC

Name: SAREPTA THERAPEUTICS INC (SRPT) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Public company

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About SAREPTA THERAPEUTICS INC (SRPT)

SAREPTA THERAPEUTICS INC (SRPT) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $50M. Across recent filings, tracked investors recorded 1 new positions, 0 increased, 2 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in SRPT

/100

Institutional Distribution

Added / Increased1

Reduced2

Exited0

BearishBullish

Crowded Trade Score™

How many top investors track SRPT

/100

Emerging Interest

4investors

A small number of top investors own this.

UndiscoveredCrowded

151015+

SRPT Ownership Composition

How SAREPTA THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type

Other

99% of tracked value

Institutions

tracked investors

Total Reported

$79.8M

combined 13F value

Other99.2%
Hedge Funds0.8%

Other(3)

99.2%

Hedge Funds(1)

0.8%

Tracked investors reporting SRPT

Investor	Firm	Shares	Market value	% of portfolio	As of
Ken Griffin	Citadel Advisors	2.3M	$49.6M	0.01%	Mar 31, 2026
Izzy Englander	Millennium Management	1.2M	$26.6M	0.01%	Mar 31, 2026
Ray Dalio	Bridgewater Associates	134.3K	$2.9M	0.01%	Mar 31, 2026
Steve Cohen	Point72 Asset Management	31K	$674.6K	0.00%	Mar 31, 2026

Ken GriffinMar 31, 2026
Citadel Advisors
Shares
2.3M
Value
$49.6M
% Portfolio
0.01%
Izzy EnglanderMar 31, 2026
Millennium Management
Shares
1.2M
Value
$26.6M
% Portfolio
0.01%
Ray DalioMar 31, 2026
Bridgewater Associates
Shares
134.3K
Value
$2.9M
% Portfolio
0.01%
Steve CohenMar 31, 2026
Point72 Asset Management
Shares
31K
Value
$674.6K
% Portfolio
0.00%

Recent activity

Investor	Action	Δ %	Current value	Filing date
Ray Dalio	Reduced	-52.14%	$2.9M	May 15, 2026
Ray Dalio	Reduced	-20.36%	$6M	Feb 13, 2026
Ray Dalio	New	—	$6.8M	Nov 13, 2025

Ray Dalio
Reduced
$2.9M(-52.14%)May 15, 2026
Ray Dalio
Reduced
$6M(-20.36%)Feb 13, 2026
Ray Dalio
New
$6.8MNov 13, 2025

Frequently asked questions

How many institutional investors hold SRPT?: 4 tracked institutional investors disclosed a position in SRPT (SAREPTA THERAPEUTICS INC) in their most recent 13F filing.
Who is the largest institutional holder of SRPT?: Ken Griffin, Citadel Advisors, holds the largest disclosed position in SRPT, valued at $50M.
Did institutional ownership of SRPT increase or decrease?: Across recent 13F filings, tracked investors recorded 1 new positions, 0 increased, 2 reduced, and 0 fully exited SRPT.
Where does this SRPT ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.